{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Corbus Pharmaceuticals Holdings, Inc."},"Symbol":{"label":"Symbol","value":"CRBP"},"Address":{"label":"Address","value":"500 RIVER RIDGE DRIVE,SECOND FLOOR, NORWOOD, Massachusetts, 02062, United States"},"Phone":{"label":"Phone","value":"+1 617 963-0100"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Corbus Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for endocannabinoid or immune system. The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus."},"CompanyUrl":{"label":"Company Url","value":"https://www.corbuspharma.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Dominic Smethurst","title":"Chief Medical Officer"},{"name":"Yuval Cohen","title":"Chief Executive Officer & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}